Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Tofacitinib + NB-UVB vs Azathioprine + NB-UVB in Vitiligo
NCT07044141Phase 1Active, not recruiting
- Sponsor
- Lahore General Hospital
- Start
- Mar 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of tofacitinib in Vitiligo (2 arms), sponsored by Lahore General Hospital. Primary endpoint: Vitiligo Area Scoring Index Improvement at 6 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07044141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044141.